Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Sino Biopharmaceutical Limited (1177.HK)
Hong Kong, HK
Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People’s Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines, including anlotinib hydrochloride capsules under Focus V brand, penpulimab injection under Annike brand, efbemalenograstin alfa injection under Yilishu brand, benmelstobart injection under Andewei brand, unecritinib fumarate capsules under Anboni brand, envonalkib citrate capsule under Anluoqing brand, garsorasib tablets under Anfangning brand, bevacizumab injection under Anbeisi brand, rituximab injection under Delituo brand, trastuzumab for injection under Saituo brand, and pertuzumab injection, under Paletan brand; liver disease medications, such as magnesium isoglycyrrhizinate injection under Tianqing Ganmei brand and entecavir dispersible tablets under Runzhong brand; and respiratory system medicines comprising budesonide suspension for inhalation under Tianqing suchang brand, and colistimethate sodium for injection under Tianyun brand. It also provides surgery/analgesia medicines, including flurbiprofen cataplasms under the brand Zepolas, limaprost tablets under the brand Kailitong, and recombinant human coagulation factor VIII for injection under the brand Anhengji. In addition, the company develops liver disease drugs, such as Lanifibranor and TQA2225; respiratory system drugs comprising TDI01, TQC2731, TCR1672, TQC3721, and TQH2722; and surgery/analgesia drugs, including PL-5, an antimicrobial peptide, TRD205, an AT2R inhibitor, and TRD303, a ropivacaine sustained-release solution. Further, it is involved in the long-term investments; and healthcare and hospital business. The company was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +3.74% | -4.41% | -7.93% | -17.52% | -29.22% | -19.26% | +12.13% | +33.42% | -42.78% | +112.34% | +5,674.13% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 3 | 0 |
| Buy | 17 | -1 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Pharmaceuticals: +7.8%+10.3% ★ Q4'25: +9.8% (vs Q4'24)
-
EPS growth Medical - Pharmaceuticals: +20.2%-31.6% Q4'25: -307.1% (vs Q4'24)
-
FCF margin FCF growth · Medical - Pharmaceuticals: +43.3%+22.0% ★ Q4'25: +20.3% (vs Q4'24)
-
EBIT margin Medical - Pharmaceuticals: +6.8%+19.8% ★ Q4'25: +20.2% (vs Q4'24)
-
ROIC Medical - Pharmaceuticals: +6.1%+13.5% ★ Q4'25: +9.7% (vs Q4'24)
-
Share dilution Medical - Pharmaceuticals: +0.0%-1.3% ★ Q4'25: -1.0% (vs Q4'24)
-
Debt / EBITDA Net debt/EBITDA · Medical - Pharmaceuticals: 0.21×2.22× ★ Q4'25: 2.42× (vs Q4'24)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2010 actual |
Dec 2011 actual |
Dec 2012 actual |
Dec 2013 actual |
Dec 2014 actual |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 18 Rev. Ana. 13 EPS Ana. |
Dec 2027 18 Rev. Ana. 12 EPS Ana. |
Dec 2028 13 Rev. Ana. 8 EPS Ana. |
Dec 2029 12 Rev. Ana. 6 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
3.48B
est: 3.59B (-2.9%)
|
4.68B
est: 4.69B (-0.2%)
|
6.70B
est: 6.59B (+1.7%)
|
7.74B
est: 8.04B (-3.8%)
|
9.90B
est: 9.89B (+0.1%)
|
12.18B
est: 15.31B (-20.4%)
|
14.17B
est: 15.92B (-11.0%)
|
14.82B
est: 17.81B (-16.8%)
|
20.89B
est: 23.48B (-11.0%)
|
24.23B
est: 28.06B (-13.6%)
|
23.65B
est: 28.42B (-16.8%)
|
26.86B
est: 34.13B (-21.3%)
|
26.03B
est: 33.73B (-22.8%)
|
26.20B
est: 25.85B (+1.4%)
|
28.87B
est: 29.16B (-1.0%)
|
31.83B
est: 32.83B (-3.0%)
|
36.38B
35.68B – 37.59B
+10.8% YoY
|
39.72B
37.87B – 42.95B
+9.2% YoY
|
44.09B
42.61B – 46.65B
+11.0% YoY
|
47.49B
45.90B – 50.26B
+7.7% YoY
|
| EBITDA |
1.00B
est: 629.91M (+59.5%)
|
925.06M
est: 1.00B (-7.9%)
|
1.54B
est: 891.79M (+72.6%)
|
1.85B
est: 1.44B (+28.7%)
|
2.48B
est: 1.80B (+37.5%)
|
3.25B
est: 2.95B (+10.1%)
|
3.60B
est: 2.85B (+26.2%)
|
4.62B
est: 2.75B (+67.7%)
|
6.15B
est: 4.85B (+26.7%)
|
7.37B
est: 12.84B (-42.6%)
|
5.66B
est: 5.43B (+4.3%)
|
19.87B
est: 6.63B (+199.9%)
|
6.69B
est: 8.40B (-20.3%)
|
6.98B
est: 8.80B (-20.7%)
|
6.11B
est: 10.13B (-39.7%)
|
7.26B
est: 11.18B (-35.1%)
|
12.39B
12.15B – 12.80B
+10.8% YoY
|
13.53B
12.90B – 14.63B
+9.2% YoY
|
15.01B
14.51B – 15.89B
+11.0% YoY
|
16.17B
15.63B – 17.12B
+7.7% YoY
|
| EBIT |
931.75M
est: 850.58M (+9.5%)
|
815.03M
est: 1.24B (-34.3%)
|
1.39B
est: 1.16B (+20.1%)
|
1.67B
est: 1.78B (-6.2%)
|
2.27B
est: 1.85B (+22.7%)
|
2.95B
est: 2.94B (+0.4%)
|
3.28B
est: 3.16B (+3.9%)
|
4.27B
est: 3.12B (+36.8%)
|
11.58B
est: 5.57B (+107.8%)
|
5.92B
est: 13.70B (-56.8%)
|
4.10B
est: 6.18B (-33.6%)
|
18.88B
est: 7.54B (+150.3%)
|
5.64B
est: 9.56B (-41.0%)
|
5.91B
est: 7.87B (-24.9%)
|
5.17B
est: 13.86B (-62.7%)
|
6.29B
est: 9.99B (-37.0%)
|
11.07B
10.86B – 11.44B
+10.8% YoY
|
12.09B
11.53B – 13.07B
+9.2% YoY
|
13.42B
12.97B – 14.20B
+11.0% YoY
|
14.46B
13.97B – 15.30B
+7.7% YoY
|
| Net Income |
483.12M
est: 422.27M (+14.4%)
|
374.56M
est: 646.29M (-42.0%)
|
717.23M
est: 539.46M (+33.0%)
|
810.13M
est: 883.39M (-8.3%)
|
1.21B
est: 1.01B (+19.7%)
|
1.49B
est: 1.77B (-16.0%)
|
1.71B
est: 1.76B (-2.5%)
|
2.17B
est: 1.72B (+26.5%)
|
9.05B
est: 3.13B (+188.9%)
|
4.69B
est: 10.75B (-56.3%)
|
2.77B
est: 2.93B (-5.5%)
|
14.61B
est: 3.58B (+308.1%)
|
2.54B
est: 1.88B (+35.2%)
|
2.33B
est: 1.99B (+17.0%)
|
3.50B
est: 2.84B (+23.1%)
|
2.34B
est: 4.51B (-48.1%)
|
3.69B
3.68B – 4.87B
-18.2% YoY
|
3.99B
3.75B – 5.60B
+8.0% YoY
|
5.26B
4.22B – 6.30B
+31.8% YoY
|
5.48B
5.24B – 5.90B
+4.2% YoY
|
| SGA |
1.89B
est: 1.81B (+4.3%)
|
2.47B
est: 2.53B (-2.2%)
|
3.53B
est: 3.56B (-0.9%)
|
3.95B
est: 4.35B (-9.3%)
|
4.93B
est: 4.92B (+0.2%)
|
5.97B
est: 7.23B (-17.4%)
|
6.79B
est: 7.04B (-3.5%)
|
6.90B
est: 6.80B (+1.5%)
|
10.27B
est: 9.96B (+3.1%)
|
11.91B
est: 12.20B (-2.4%)
|
11.63B
est: 12.90B (-9.9%)
|
12.70B
est: 15.75B (-19.3%)
|
12.56B
est: 19.96B (-37.1%)
|
11.07B
est: 11.44B (-3.2%)
|
12.16B
est: 13.16B (-7.6%)
|
13.14B
est: 14.52B (-9.5%)
|
16.10B
15.79B – 16.63B
+10.8% YoY
|
17.57B
16.75B – 19.00B
+9.2% YoY
|
19.50B
18.85B – 20.64B
+11.0% YoY
|
21.01B
20.31B – 22.23B
+7.7% YoY
|
| EPS |
0.03
est: 0.02 (+35.4%)
|
0.02
est: 0.02 (+23.5%)
|
0.04
est: 0.03 (+35.9%)
|
0.05
est: 0.04 (+13.3%)
|
0.07
est: 0.05 (+36.0%)
|
0.09
est: 0.09 (-0.9%)
|
0.10
est: 0.11 (-8.7%)
|
0.13
est: 0.13 (+0.8%)
|
0.49
est: 0.15 (+230.1%)
|
0.25
est: 0.17 (+47.5%)
|
0.15
est: 0.14 (+8.1%)
|
0.78
est: 0.70 (+11.1%)
|
0.11
est: 0.19 (-41.1%)
|
0.08
est: 0.11 (-26.8%)
|
0.20
est: 0.15 (+29.0%)
|
0.13
est: 0.26 (-49.8%)
|
0.24
0.20 – 0.27
-8.6% YoY
|
0.26
0.21 – 0.31
+9.8% YoY
|
0.29
0.23 – 0.35
+10.3% YoY
|
0.30
0.29 – 0.33
+5.9% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B | 3/5 | 4/5 | 4/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-28 | B | 3/5 | 4/5 | 4/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-27 | B | 3/5 | 4/5 | 4/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-26 | B | 3/5 | 4/5 | 4/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-22 | B | 3/5 | 4/5 | 4/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-21 | B | 3/5 | 4/5 | 4/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-20 | B | 3/5 | 4/5 | 4/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-19 | C | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-18 | C | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-15 | C | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-14 | C | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-13 | C | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-12 | C | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-11 | C | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-08 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-29 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-28 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-27 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-24 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-23 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-22 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-21 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-20 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-17 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-16 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-15 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| S. Y. Tse | Chief Executive Officer & Executive Director | 75M | male |
| Ping Tse | Founder & Senior Executive Vice Chairman | 52M | male |
| Cheung Ling Cheng | Executive Vice Chairwoman of the Board | 46M | female |
| Y. Y. Tse | Executive Chairwoman of the Board | 43M | female |
| Hsin Tse | Senior Vice President & Executive Director | 5M | male |
| Zhoushan Tian | Executive Director | 2M | male |
| Rongjun Liu | Head of Clinical Development for Autoimmune Diseases | — | — |
| Meng Liu | Head of Clinical Development for Chronic Diseases | — | — |
| Song Jin | Vice President of Public Affairs & ESG | — | male |
| Toogood Ben | Chief Executive Officer of InvoX & Head of Globalization | — | male |
| Xiaoyan Kang | Chief Medical Officer | — | female |
| Kuen Lai | Company Secretary | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 1177.HK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
